Lista de obras -

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

artículo científico publicado en 2016

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors

artículo científico publicado en 2019

A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1.

artículo científico publicado en 2016

ANGIOTROPISM IN RECURRENT CUTANEOUS SQUAMOUS CELL CARCINOMA: IMPLICATIONS FOR REGIONAL TUMOR RECURRENCE AND EXTRAVASCULAR MIGRATORY SPREAD

artículo científico publicado en 2018

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

artículo científico publicado en 2022

Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

artículo científico publicado en 2018

B cells and tertiary lymphoid structures promote immunotherapy response

artículo científico publicado en 2020

BAP1-inactivated melanocytic tumor with preserved BAP1 expression? Morphology to the rescue!

artículo científico publicado en 2020

Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma

artículo científico publicado en 2014

Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor

artículo científico publicado en 2018

Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial

artículo científico publicado en 2016

Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients

artículo científico publicado en 2016

Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer

scientific article published on 11 January 2019

Dermatologic Toxicity from Novel Therapy using Antimicrobial Peptide LL-37 in Melanoma: A Detailed Examination of the Clinicopathologic Features

artículo científico publicado en 2018

Erratum to: A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1.

artículo científico publicado en 2017

Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response

artículo científico publicado en 2019

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.

artículo científico publicado en 2017

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

artículo científico publicado en 2017

Immunohistochemical markers informing the diagnosis of sebaceous carcinoma and its distinction from its mimics: Adipophilin and factor XIIIa to the rescue?

artículo científico publicado en 2017

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.

artículo científico publicado en 2017

Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features

artículo científico publicado en 2019

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

artículo científico publicado en 2015

Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade.

artículo científico publicado en 2017

Mutational landscape of aggressive cutaneous squamous cell carcinoma

artículo científico publicado en 2014

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

artículo científico publicado en 2018

Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.

artículo científico publicado en 2016

Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study.

artículo científico publicado en 2017

Post-radiation vascular lesions of the breast

artículo científico publicado en 2018

Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

artículo científico publicado en 2018

Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma

artículo científico publicado en 2020

Spitzoid melanoma with histopathological features of ALK gene rearrangement exhibiting ALK copy number gain: a novel mechanism of ALK activation in spitzoid neoplasia

artículo científico publicado en 2018

Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions

scientific article published on 24 July 2018

Update on Merkel Cell Carcinoma.

artículo científico publicado en 2018

Lista de obras de

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors

A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1.

ANGIOTROPISM IN RECURRENT CUTANEOUS SQUAMOUS CELL CARCINOMA: IMPLICATIONS FOR REGIONAL TUMOR RECURRENCE AND EXTRAVASCULAR MIGRATORY SPREAD

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

B cells and tertiary lymphoid structures promote immunotherapy response

BAP1-inactivated melanocytic tumor with preserved BAP1 expression? Morphology to the rescue!

Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma

Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor

Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial

Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients

Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer

Dermatologic Toxicity from Novel Therapy using Antimicrobial Peptide LL-37 in Melanoma: A Detailed Examination of the Clinicopathologic Features

Erratum to: A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1.

Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Immunohistochemical markers informing the diagnosis of sebaceous carcinoma and its distinction from its mimics: Adipophilin and factor XIIIa to the rescue?

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.

Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade.

Mutational landscape of aggressive cutaneous squamous cell carcinoma

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.

Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study.

Post-radiation vascular lesions of the breast

Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma

Spitzoid melanoma with histopathological features of ALK gene rearrangement exhibiting ALK copy number gain: a novel mechanism of ALK activation in spitzoid neoplasia

Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions

Update on Merkel Cell Carcinoma.